Position paper ANMCO

Raccomandazioni per il follow-up del paziente con tromboembolia polmonare

Carlo D'Agostino, Pietro Zonzin, Iolanda Enea, Michele Massimo Gulizia, Walter Ageno, Piergiuseppe Agostoni, Michele Azzarito, Cecilia Becattini, Amedeo Bongarzoni, Francesca Bux, Franco Casazza, Nicoletta Corrieri, Michele D'Alto, Nicola D'Amato, Andrea Maria D'Armini, Maria Grazia De Natale, Giovanni Di Minno, Giuseppe Favretto, Lucia Filippi, Valentina Grazioli & 5 others Gualtiero Palareti, Raffaele Pesavento, Loris Roncon, Laura Scelsi, Antonella Tufano

Research output: Contribution to journalReview article

Abstract

Venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is the third most common cause of cardiovascular death. The management of the acute phase of VTE is well described in several papers and guidelines whereas the management of the follow-up of the patients affected from VTE is less defined. This position paper of the Italian Association of Hospital Cardiologists (ANMCO) tries to fill the gap using currently available evidence and the opinion of the experts to suggest the most useful way to manage patients in the chronic phase. The clinical and laboratory tests acquired during the acute phase of the disease drives the decision of the following period. Acquired or congenital thrombophilic factors may be identified to explain an apparently not provoked VTE. In some patients, a not yet clinically evident cancer could be the trigger of VTE and this could lead to a different strategy. The main target of the post-acute management is to prevent relapse of the disease and to identify those patients who could worsen or develop chronic thromboembolic pulmonary hypertension. The knowledge of the etiopathogenetic ground is important to address the therapeutic approach, choos-ing the best antithrombotic strategy and deciding how long therapy should last. During the follow-up period, prognostic stratification should be updated on the basis of new evidences eventually acquired. Treatment of VTE is mainly based on oral or parenteral anticoagulation. Oral direct inhibitors of coagulation represent an interesting new therapy for the acute and extended period of treatment.

Original languageItalian
Pages (from-to)68S-109S
JournalGiornale Italiano di Cardiologia
Volume17
Issue number9
Publication statusPublished - Sep 1 2016

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

D'Agostino, C., Zonzin, P., Enea, I., Gulizia, M. M., Ageno, W., Agostoni, P., ... Tufano, A. (2016). Position paper ANMCO: Raccomandazioni per il follow-up del paziente con tromboembolia polmonare. Giornale Italiano di Cardiologia, 17(9), 68S-109S.

Position paper ANMCO : Raccomandazioni per il follow-up del paziente con tromboembolia polmonare. / D'Agostino, Carlo; Zonzin, Pietro; Enea, Iolanda; Gulizia, Michele Massimo; Ageno, Walter; Agostoni, Piergiuseppe; Azzarito, Michele; Becattini, Cecilia; Bongarzoni, Amedeo; Bux, Francesca; Casazza, Franco; Corrieri, Nicoletta; D'Alto, Michele; D'Amato, Nicola; Maria D'Armini, Andrea; De Natale, Maria Grazia; Di Minno, Giovanni; Favretto, Giuseppe; Filippi, Lucia; Grazioli, Valentina; Palareti, Gualtiero; Pesavento, Raffaele; Roncon, Loris; Scelsi, Laura; Tufano, Antonella.

In: Giornale Italiano di Cardiologia, Vol. 17, No. 9, 01.09.2016, p. 68S-109S.

Research output: Contribution to journalReview article

D'Agostino, C, Zonzin, P, Enea, I, Gulizia, MM, Ageno, W, Agostoni, P, Azzarito, M, Becattini, C, Bongarzoni, A, Bux, F, Casazza, F, Corrieri, N, D'Alto, M, D'Amato, N, Maria D'Armini, A, De Natale, MG, Di Minno, G, Favretto, G, Filippi, L, Grazioli, V, Palareti, G, Pesavento, R, Roncon, L, Scelsi, L & Tufano, A 2016, 'Position paper ANMCO: Raccomandazioni per il follow-up del paziente con tromboembolia polmonare', Giornale Italiano di Cardiologia, vol. 17, no. 9, pp. 68S-109S.
D'Agostino, Carlo ; Zonzin, Pietro ; Enea, Iolanda ; Gulizia, Michele Massimo ; Ageno, Walter ; Agostoni, Piergiuseppe ; Azzarito, Michele ; Becattini, Cecilia ; Bongarzoni, Amedeo ; Bux, Francesca ; Casazza, Franco ; Corrieri, Nicoletta ; D'Alto, Michele ; D'Amato, Nicola ; Maria D'Armini, Andrea ; De Natale, Maria Grazia ; Di Minno, Giovanni ; Favretto, Giuseppe ; Filippi, Lucia ; Grazioli, Valentina ; Palareti, Gualtiero ; Pesavento, Raffaele ; Roncon, Loris ; Scelsi, Laura ; Tufano, Antonella. / Position paper ANMCO : Raccomandazioni per il follow-up del paziente con tromboembolia polmonare. In: Giornale Italiano di Cardiologia. 2016 ; Vol. 17, No. 9. pp. 68S-109S.
@article{9eadb57cff9d49e29316457efe415455,
title = "Position paper ANMCO: Raccomandazioni per il follow-up del paziente con tromboembolia polmonare",
abstract = "Venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is the third most common cause of cardiovascular death. The management of the acute phase of VTE is well described in several papers and guidelines whereas the management of the follow-up of the patients affected from VTE is less defined. This position paper of the Italian Association of Hospital Cardiologists (ANMCO) tries to fill the gap using currently available evidence and the opinion of the experts to suggest the most useful way to manage patients in the chronic phase. The clinical and laboratory tests acquired during the acute phase of the disease drives the decision of the following period. Acquired or congenital thrombophilic factors may be identified to explain an apparently not provoked VTE. In some patients, a not yet clinically evident cancer could be the trigger of VTE and this could lead to a different strategy. The main target of the post-acute management is to prevent relapse of the disease and to identify those patients who could worsen or develop chronic thromboembolic pulmonary hypertension. The knowledge of the etiopathogenetic ground is important to address the therapeutic approach, choos-ing the best antithrombotic strategy and deciding how long therapy should last. During the follow-up period, prognostic stratification should be updated on the basis of new evidences eventually acquired. Treatment of VTE is mainly based on oral or parenteral anticoagulation. Oral direct inhibitors of coagulation represent an interesting new therapy for the acute and extended period of treatment.",
keywords = "Deep vein thrombosis, Prognosis, Pulmonary embolism, Venous thromboembolism",
author = "Carlo D'Agostino and Pietro Zonzin and Iolanda Enea and Gulizia, {Michele Massimo} and Walter Ageno and Piergiuseppe Agostoni and Michele Azzarito and Cecilia Becattini and Amedeo Bongarzoni and Francesca Bux and Franco Casazza and Nicoletta Corrieri and Michele D'Alto and Nicola D'Amato and {Maria D'Armini}, Andrea and {De Natale}, {Maria Grazia} and {Di Minno}, Giovanni and Giuseppe Favretto and Lucia Filippi and Valentina Grazioli and Gualtiero Palareti and Raffaele Pesavento and Loris Roncon and Laura Scelsi and Antonella Tufano",
year = "2016",
month = "9",
day = "1",
language = "Italian",
volume = "17",
pages = "68S--109S",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "9",

}

TY - JOUR

T1 - Position paper ANMCO

T2 - Raccomandazioni per il follow-up del paziente con tromboembolia polmonare

AU - D'Agostino, Carlo

AU - Zonzin, Pietro

AU - Enea, Iolanda

AU - Gulizia, Michele Massimo

AU - Ageno, Walter

AU - Agostoni, Piergiuseppe

AU - Azzarito, Michele

AU - Becattini, Cecilia

AU - Bongarzoni, Amedeo

AU - Bux, Francesca

AU - Casazza, Franco

AU - Corrieri, Nicoletta

AU - D'Alto, Michele

AU - D'Amato, Nicola

AU - Maria D'Armini, Andrea

AU - De Natale, Maria Grazia

AU - Di Minno, Giovanni

AU - Favretto, Giuseppe

AU - Filippi, Lucia

AU - Grazioli, Valentina

AU - Palareti, Gualtiero

AU - Pesavento, Raffaele

AU - Roncon, Loris

AU - Scelsi, Laura

AU - Tufano, Antonella

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is the third most common cause of cardiovascular death. The management of the acute phase of VTE is well described in several papers and guidelines whereas the management of the follow-up of the patients affected from VTE is less defined. This position paper of the Italian Association of Hospital Cardiologists (ANMCO) tries to fill the gap using currently available evidence and the opinion of the experts to suggest the most useful way to manage patients in the chronic phase. The clinical and laboratory tests acquired during the acute phase of the disease drives the decision of the following period. Acquired or congenital thrombophilic factors may be identified to explain an apparently not provoked VTE. In some patients, a not yet clinically evident cancer could be the trigger of VTE and this could lead to a different strategy. The main target of the post-acute management is to prevent relapse of the disease and to identify those patients who could worsen or develop chronic thromboembolic pulmonary hypertension. The knowledge of the etiopathogenetic ground is important to address the therapeutic approach, choos-ing the best antithrombotic strategy and deciding how long therapy should last. During the follow-up period, prognostic stratification should be updated on the basis of new evidences eventually acquired. Treatment of VTE is mainly based on oral or parenteral anticoagulation. Oral direct inhibitors of coagulation represent an interesting new therapy for the acute and extended period of treatment.

AB - Venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is the third most common cause of cardiovascular death. The management of the acute phase of VTE is well described in several papers and guidelines whereas the management of the follow-up of the patients affected from VTE is less defined. This position paper of the Italian Association of Hospital Cardiologists (ANMCO) tries to fill the gap using currently available evidence and the opinion of the experts to suggest the most useful way to manage patients in the chronic phase. The clinical and laboratory tests acquired during the acute phase of the disease drives the decision of the following period. Acquired or congenital thrombophilic factors may be identified to explain an apparently not provoked VTE. In some patients, a not yet clinically evident cancer could be the trigger of VTE and this could lead to a different strategy. The main target of the post-acute management is to prevent relapse of the disease and to identify those patients who could worsen or develop chronic thromboembolic pulmonary hypertension. The knowledge of the etiopathogenetic ground is important to address the therapeutic approach, choos-ing the best antithrombotic strategy and deciding how long therapy should last. During the follow-up period, prognostic stratification should be updated on the basis of new evidences eventually acquired. Treatment of VTE is mainly based on oral or parenteral anticoagulation. Oral direct inhibitors of coagulation represent an interesting new therapy for the acute and extended period of treatment.

KW - Deep vein thrombosis

KW - Prognosis

KW - Pulmonary embolism

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84992364750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992364750&partnerID=8YFLogxK

M3 - Articolo critico

VL - 17

SP - 68S-109S

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 9

ER -